OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/06/2026
Voltar para busca
Dado oficial do USPTO
MEDINCELL.
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
19/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 9, 42
Data de depósito
17/10/2024
Data de registro
16/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/06/2026
Última transação
19/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
FR
Examinador
KELLY, JOHN M
Unidade examinadora
N10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
MedinCell S.A.
Representantes
Jonathan M. Gelchinsky Pierce Atwood LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratorydiseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical compositions for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratorydiseases and disordersfor the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; carriers for pharmaceutical and veterinary preparations being drug delivery agents in the form of dissolvable filmscoatings for tablets that facilitate the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; bacteriological culture or cell culture mediums for pharmaceutical and veterinary preparations being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary preparations and substances for subcutaneous delivery for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders
Classe 9
Scientific apparatus and instrumentstools for injecting and administering liquid formulations into testing equipment or other drug delivery devices; laboratory apparatus and instruments for extracting excipients or active pharmaceutical ingredients from in situ forming depotsnot for medical purposes; apparatus and instruments for chemical analysisplatesglass slides or chips having multi-well arrays that can be used in chemical analysis; apparatus and instruments for measuringtesting and analysing chemical compositions; apparatus for analysing gases; weighing apparatus and instruments; measuring apparatus and instrumentsflow controllers; recorded or downloadable computer software for the quantitative long-term monitoring of the release pharmaceutical ingredients into a patient's body; computer hardware
Classe 42
Laboratory researchtesting and research laboratory analysis services in the field of drug delivery; laboratory servicesmedical research laboratories; chemical analysis; medicalscientific and industrial research in the field of long-acting injectable compositions and providing information relating thereto; pharmaceutical drug development services; pharmaceutical research and development services; rental of laboratory apparatus and instruments; design and development of laboratory and diagnostic apparatus; development and testing of algorithms and software; consultancy in the field of pharmaceutical research and development; services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticalschemical analysis and clinical trials; providing scientific research information; scientific research in the fields of medicinepharmacology and veterinary medicine
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
16/06/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
16/06/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/06/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
31/05/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/04/2026
PUBO
PUBLISHED FOR OPPOSITION
28/04/2026
GPNX
NOTIFICATION PROCESSED BY IB
23/04/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/04/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/04/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/03/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/03/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/03/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/03/2026
RFNT
REFUSAL PROCESSED BY IB
15/11/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/10/2025
RFRR
REFUSAL PROCESSED BY MPU
29/10/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
02/10/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/10/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/10/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/10/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/10/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/09/2025
CNRT
NON-FINAL ACTION WRITTEN
10/09/2025
DOCK
ASSIGNED TO EXAMINER
06/09/2025
MAFR
APPLICATION FILING RECEIPT MAILED
05/09/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/09/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/01/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEDINCELL. ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.